Jeffrey A. Hubbell

Jeffrey A. Hubbell

Eugene Bell Professor in Tissue Engineering
Institute for Molecular Engineering, University of Chicago

Jeffrey Hubbell is Professor in the Institute for Molecular Engineering of the University of Chicago. Previous to moving to Chicago, he was on the faculty of the Swiss Federal Institute of Technology Lausanne (EPFL, where he served as Director of the Institute of Bioengineering and Dean of the School of Life Sciences), the Swiss Federal Institute of Technology Zurich and University of Zurich, the California Institute of Technology, and the University of Texas in Austin.  He holds a BS from Kansas State University and a PhD from Rice University, both degrees being in chemical engineering. He was elected to the US National Academy of Engineering in 2010.

Hubbell uses biomaterials and protein engineering approaches to investigate topics in regenerative medicine and immunotherapeutics. In regenerative medicine, he focuses on biomaterial matrices that mimic the extracellular matrix and on growth factor - extracellular matrix interactions, working in a variety of animal models of regenerative medicine. In immunotherapeutics, he focuses on nanomaterials in vaccines that target lymphoid-resident antigen presenting cells and on protein engineering approaches to deliver antigen to the spleen and liver for inverse vaccines to induce tolerance to protein drugs and in autoimmunity.  His interests are both basic and translational, having founded or co-founded three biomedical companies based on his technology (Focal Inc., in Boston, acquired by Genzyme; Kuros Biosurgery AG, in Zurich, in the domain of regenerative medicine; and Anokion SA, in Lausanne, in the domain of immunological tolerance.